In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Cytori Therapeutics (NASDAQ:CYTX) and raised his price …
In a research report published Thursday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Cytori Therapeutics (NASDAQ:CYTX) with a $3.50 price …
Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Cytori Therapeutics (NASDAQ:CYTX) with a price target of $4, which represents a potential …
Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Cytori Therapeutics (NASDAQ:CYTX) with a price target of $3.50, which represents a potential …
In a research note issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Cytori Therapeutics (NASDAQ:CYTX) with a $5 price target, …
In a research report issued yesterday, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Cytori Therapeutics (NASDAQ:CYTX) with a price target …
Cytori Therapeutics (NASDAQ:CYTX) announced that BARDA executed the option to fund the continued development of Cytori Cell Therapy for thermal burn injuries. The current …
In reaction to yesterday’s news that Cytori Therapeutics (CYTX), has been selected to supply adipose-derived regenerative cells for the Cardiovascular Cell Therapy Research Network’s (CCTRN) …
